Stockreport

Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of ...

IMMUNE DESIGN CORP COMMON STOCK  (IMDZ) 
Last immune design corp common stock earnings: 11/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.immunedesign.com/investor-relations
PDF Overall Response Rate (ORR) of 46% in Patients Receiving the Combination TLR4 Biomarker Continued to Show Higher Response Rate for Patients with High TLR4 Expression (71 [Read more]